Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Risk Assessment in Patients with Myelodysplastic Neoplasms Using the Molecular International Prognostic Scoring System: A Single-Center Study from the Czech Republic

Jitka Vesela, Hana Votavova, Monika Kaisrlikova, Zuzana Lenertova, David Kundrat, Iva Trsová, Sarka Ransdorfova, Dana Mikulenkova, Jaroslav Cermak, Monika Belickova

Blood (2022) 140 (Supplement 1): 4098–4099.

https://doi.org/10.1182/blood-2022-165903

Published: 2022

Journal Articles

An Analysis of Real Life Data Obtained from 30 Years Follow-up of Primary Myelodysplastic Syndromes (MDS) Patients Confirms a Leading Role of Stem Cell Transplantation (SCT) for Achievement of Prolonged Survival

Jaroslav Cermak, MD PhD, Antonin Vitek, MD, Dana Mikulenkova, MD, Jacqueline Soukupova, MD, Jana Brezinova, Marketa Stastna, MD PhD, Veronika Valkova, MD PhD, Monika Belickova, PhD, Kyra Michalova, PhD, Petr Cetkovsky, MD MBA, PhD

Blood (2018) 132 (Supplement 1): 4372.

https://doi.org/10.1182/blood-2018-99-114987

Published: 2018

Journal Articles

Importance of Transcription Factor Nrf2 for Cereblon Expression and Clinical Response to Combination of Lenalidomide and Erythropoietin in Lower-Risk Myelodysplastic Syndromes

Radka Bokorová, MSc, Jaroslav Polak, MSc, Anna Jonasova, MD, Radana Neuwirtova, MD PhD, Marie Lauermannova, MD, Jaroslav Cermak, MD PhD, Marketa Stastna, MD PhD, Cyril Salek, Dana Mikulenkova, MD, Zuzana Zemanova, PhD, Jana Brezinova, Kyra Michalova, PhD, Denisa Myslivcova, PhD, Ota Fuchs, PhD

Blood (2018) 132 (Supplement 1): 5507.

https://doi.org/10.1182/blood-2018-99-115803

Published: 2018

Journal Articles

Measurement of Increase in Cereblon mRNA Level after Addition of Erythropoietin to Lenalidomide May Predict a Clinical Response to Combination of Both the Drugs in Patients with Lower-Risk Myelodysplastic Syndromes

Radka Bokorová, Jaroslav Polak, MSc, Arnost Kostecka, Anna Jonasova, MD PhD, Radana Neuwirtova, MD PhD, Tomas Stopka, MD PhD Assoc Proff, Marie Lauermannova, Jaroslav Cermak, MD PhD, Dana Mikulenkova, Zuzana Zemanova, PhD, Jana Brezinova, PhD, Ota Fuchs, PhD

Blood (2017) 130 (Supplement 1): 5295.

https://doi.org/10.1182/blood.V130.Suppl_1.5295.5295

Published: 2017

Journal Articles

The Prognostic Significance of TP53 Mutations for Overall Outcome in Lower-Risk MDS Patients

Monika Belickova, Jitka Vesela, Anna Jonasova, MD, Eliska Stara, Barbora Planetova, Zuzana Zemanova, Jana Brezinova, Dana Mikulenkova, Jaroslav Cermak, MD PhD As. Prof.

Blood (2014) 124 (21): 4630.

https://doi.org/10.1182/blood.V124.21.4630.4630

Published: 2014

Journal Articles

High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide

Anna T Jonasova, MD, Jaroslav Polak, Martin Vostry, Arnost Kostecka, Radka Bokorova, Radana Neuwirtova, MD, PhD, Magda Siskova, MD, Miroslav Caniga, Dana Sponerova, Jaroslav Cermak, Dana Mikulenková, MD, Jana Brezinova, PhD, Kyra Michalova, PhD, Ota Fuchs, PhD

Blood (2013) 122 (21): 1529.

https://doi.org/10.1182/blood.V122.21.1529.1529

Published: 2013

Journal Articles

PU.1 Relieves Its GATA-1-Mediated Repression near Cebpa and Cbfb During Transdifferentiation of Murine Erythroleukemia - Tool of Inducing Leukemic Blasts to Differentiate.

Pavel Burda, Nikola Curik, Juraj Kokavec, Dana Mikulenkova, MD, Arthur Skoultchi, PhD, Jiri Zavadil, PhD, Tomas Stopka, MD, PhD

Blood (2009) 114 (22): 547.

https://doi.org/10.1182/blood.V114.22.547.547

Published: 2009

Journal Articles

Modification of WPSS for the Time of Diagnosis Retains Its Prognostic Impact and Confirms Transfusion Dependency as An Important Parameter Affecting Survival in Early MDS Patients with Isolated Erythroid Dysplasia.

Jaroslav Cermak, M.D., Ph.D., Dana Mikulenkova, M.D., Petra Kacirkova, M.D., Kyra Michalova, Ph.D.

Blood (2008) 112 (11): 1654.

https://doi.org/10.1182/blood.V112.11.1654.1654

Published: 2008

Journal Articles

A Lack of Correlation between EVI1 Expression, MDS Subtype and Karyotype Abnormalities Suggests Multiple Pathways Involved in EVI1 Impact on Hematopoietic Cells in MDS Patients.

Jaroslav Cermak, MD, PhD, Ota Fuchs Ing, PhD, Dana Provaznikova, PhD, Kyra Michalova, PhD, Dana Mikulenkova, MD, Jana Brezinova, RNDr PhD, Pavel Klener, MD, PhD

Blood (2007) 110 (11): 2441.

https://doi.org/10.1182/blood.V110.11.2441.2441

Published: 2007

Journal Articles

Isolated Granulocytopenia in Patients with Unclassifiable MDS May Be Related to a Mutation of PIG-A Gene Leading to GPI-APs Deficiency Expressed Predominantly on Granulocytes.

Jaroslav Cermak, MD, PhD, Sona Pekova, MD,PhD, Iuri Marinov, MD,PhD, Dana Mikulenkova

Blood (2006) 108 (11): 2634.

https://doi.org/10.1182/blood.V108.11.2634.2634

Published: 2006

NARROW

Risk Assessment in Patients with Myelodysplastic Neoplasms Using the Molecular International Prognostic Scoring System: A Single-Center Study from the Czech Republic

An Analysis of Real Life Data Obtained from 30 Years Follow-up of Primary Myelodysplastic Syndromes (MDS) Patients Confirms a Leading Role of Stem Cell Transplantation (SCT) for Achievement of Prolonged Survival

Importance of Transcription Factor Nrf2 for Cereblon Expression and Clinical Response to Combination of Lenalidomide and Erythropoietin in Lower-Risk Myelodysplastic Syndromes

Measurement of Increase in Cereblon mRNA Level after Addition of Erythropoietin to Lenalidomide May Predict a Clinical Response to Combination of Both the Drugs in Patients with Lower-Risk Myelodysplastic Syndromes

The Prognostic Significance of TP53 Mutations for Overall Outcome in Lower-Risk MDS Patients

High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide

PU.1 Relieves Its GATA-1-Mediated Repression near Cebpa and Cbfb During Transdifferentiation of Murine Erythroleukemia - Tool of Inducing Leukemic Blasts to Differentiate.

Modification of WPSS for the Time of Diagnosis Retains Its Prognostic Impact and Confirms Transfusion Dependency as An Important Parameter Affecting Survival in Early MDS Patients with Isolated Erythroid Dysplasia.

A Lack of Correlation between EVI1 Expression, MDS Subtype and Karyotype Abnormalities Suggests Multiple Pathways Involved in EVI1 Impact on Hematopoietic Cells in MDS Patients.

Isolated Granulocytopenia in Patients with Unclassifiable MDS May Be Related to a Mutation of PIG-A Gene Leading to GPI-APs Deficiency Expressed Predominantly on Granulocytes.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only